[Pharmacoeconomic evaluation for the treatment of rheumatoid arthritis].
To conduct pharmacoeconomic evaluations for the two therapies of rheumatoid arthritis (RA). An expert survey was conducted on the cost and effectiveness of two RA therapies of methotrexate (MTX) alone and recombinant human tumor necrosis factor-α receptor II:IgG Fc fusion protein (rhTNFR:Fc) plus MTX, followed by simulation estimates, and cost-effectiveness analysis on the basis of pharmacoeconomic Markov model. MTX alone and rhTNFR:Fc plus MTX cost RMB 1422 Yuan and RMB13 000 Yuan respectively per treatment cycle (3 months). Five-year Markov model showed that the incremental cost-effectiveness ratio of rhTNFR:Fc plus MTX was RMB 99 662 Yuan per QALY when compared with MTX alone. And it was lower than the threshold of willingness to pay. The patients with RA on the combined treatment of rhTNFR:Fc and MTX may have potential long-run economic advantage over those on the treatment of MTX alone.